Related Experiment Video

Updated: Jun 2, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development

Carolien Konijnenberg1, Annika Melinder

  • 1Norwegian Centre for Addiction Research, Institute of Psychiatry, University of Oslo, Oslo, Norway. carolien.konijnenberg@psykologi.uio.no

Child Neuropsychology : a Journal on Normal and Abnormal Development in Childhood and Adolescence
|April 12, 2011
PubMed

Insights

Prenatal exposure to long-lasting opioids like methadone and buprenorphine, used in opioid maintenance therapy, impacts children's cognitive development. This review examines effects on growth, brain development, and other factors, identifying research gaps.

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Pharmacology

Background:

  • Increasing rates of opioid use disorder and opioid maintenance therapy (OMT).
  • Rising incidence of prenatal exposure to long-acting opioids (e.g., methadone, buprenorphine).
  • Need for comprehensive understanding of developmental outcomes in exposed children.

Purpose of the Study:

  • To review existing literature on the cognitive development of children exposed prenatally to OMT.
  • To synthesize findings on physical, neurological, and system-based effects.
  • To identify critical areas for future research.

Main Methods:

  • Systematic literature review of studies on prenatal opioid exposure and child development.
  • Analysis of research examining effects on prematurity, somatic growth, and brain development (volume, myelination).
  • Inclusion of studies on endocrine and neurotransmitter systems, social-environmental, and genetic factors.

Main Results:

  • Prenatal opioid exposure is associated with effects on prematurity, somatic growth, and brain development.
  • Impacts on endocrine and neurotransmitter systems are observed.
  • Social-environmental and genetic factors also play a role in developmental outcomes.

Conclusions:

  • Prenatal exposure to opioids via OMT presents complex challenges to child development.
  • Further research is crucial to fully elucidate long-term cognitive and developmental trajectories.
  • Understanding these factors can inform interventions and support for affected children and families.

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

Related Concept Videos

Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...